Thus, MYBMIM offers a pharmacologic strategy to block leukemogenic transcriptional coactivation as a therapy for AML and other human cancers with aberrant MYB or CBP/P300 activities. This evidence concerns the gene CREBBP and acute myeloid leukemia.